Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers

Seminars in Hematology · Published 2025-08-01 · DOI 10.1053/j.seminhematol.2025.08.004

Authors being retrieved — see the publisher record. https://doi.org/10.1053/j.seminhematol.2025.08.004

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Dual bispecific protein engager–armed T cells targeting BCMA and B7-H3 overcome antigen heterogeneity in multiple myeloma · BIOMEDICINE & PHARMACOTHERAPY · 2026 · Cites or is cited by this article
Menin inhibition for the treatment of acute leukemia · Seminars in Hematology · 2025 · Same journal
Closing the Disease Modification Gap: Emerging Therapies in Myelofibrosis Beyond JAK Inhibition · Seminars in Hematology · 2026 · Same journal
outside front cover, PMS 8883 metallic AND 4/C · Seminars in Hematology · 2025 · Same journal
Resolving leukemic stem cell heterogeneity and plasticity with single-cell multiomics · Seminars in Hematology · 2025 · Same journal
Harnessing single-domain antibodies for CAR-T and bispecific antibody development · Seminars in Hematology · 2025 · Same journal
Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis · Seminars in Hematology · 2026 · Same journal
Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications · Seminars in Hematology · 2025 · Same journal
The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology · Seminars in Hematology · 2025 · Same journal
Evolving insights into mitochondrial presence in RBC in sickle cell disease: Red blood cell and reticulocyte pathophysiology, therapeutic strategies, and future directions · Seminars in Hematology · 2026 · Same journal